Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease

Alzheimer’s disease (AD) affects several important molecules in brain metabolism. The resulting neurochemical changes can be quantified non-invasively in localized brain regions using in vivo single-voxel proton magnetic resonance spectroscopy (SV 1H MRS). Although the often heralded diagnostic potential of MRS in AD largely remains unfulfilled, more recent use of high magnetic fields has led to significantly improved signal-to-noise ratios and spectral resolutions, thereby allowing clinical applications with increased measurement reliability. The present article provides a comprehensive review of SV 1H MRS studies on AD at high magnetic fields (3.0 Tesla and above). This review suggests that patterned regional differences and longitudinal alterations in several neurometabolites are associated with clinically established AD. Changes in multiple metabolites are identifiable even at early stages of AD development. By combining information of neurochemicals in different brain regions revealing either pathological or compensatory changes, high field MRS can be evaluated in AD diagnosis and in the detection of treatment effects. To achieve this, standardization of data acquisition and analytical approaches is needed.

[1]  S. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.

[2]  P. Barker,et al.  MR spectroscopy and spectroscopic imaging of the brain. , 2011, Methods in molecular biology.

[3]  C. Jack,et al.  Evidence for ordering of Alzheimer disease biomarkers. , 2011, Archives of neurology.

[4]  P. Fraser,et al.  Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. , 2000, The Journal of biological chemistry.

[5]  H. Braak,et al.  On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and lamina-specific pathology in Alzheimer's disease , 2004, Acta Neuropathologica.

[6]  H. Ripps,et al.  Review: Taurine: A “very essential” amino acid , 2012, Molecular vision.

[7]  Norbert Schuff,et al.  White matter damage in frontotemporal dementia and Alzheimer's disease measured by diffusion MRI , 2009, Brain : a journal of neurology.

[8]  KLAUS-DIETMARMERFSOLDT Jensfrahm Localized Proton Spectroscopy Using Stimulated Echoes , 2004 .

[9]  W M Bovée,et al.  Improved quantification of in vivo1H NMR spectra by optimization of signal acquisition and processing and by incorporation of prior knowledge into the spectral fitting , 1990, Magnetic resonance in medicine.

[10]  R. Edden,et al.  In vivo magnetic resonance spectroscopy of GABA: a methodological review. , 2012, Progress in nuclear magnetic resonance spectroscopy.

[11]  N. Fayed,et al.  Magnetic resonance imaging based clinical research in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[12]  S. Provencher Automatic quantitation of localized in vivo 1H spectra with LCModel , 2001, NMR in biomedicine.

[13]  K. Kantarci Proton MRS in mild cognitive impairment , 2013, Journal of magnetic resonance imaging : JMRI.

[14]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[15]  Klaas Nicolay,et al.  1H MR spectroscopy of the brain: absolute quantification of metabolites. , 2006, Radiology.

[16]  K Ugurbil,et al.  In vivo 1H NMR spectroscopy of the human brain at 7 T , 2001, Magnetic resonance in medicine.

[17]  R. Dringen,et al.  Metabolism and functions of glutathione in brain , 2000, Progress in Neurobiology.

[18]  K. Uğurbil,et al.  In vivo 1H NMR spectroscopy of the human brain at high magnetic fields: Metabolite quantification at 4T vs. 7T , 2009, Magnetic resonance in medicine.

[19]  T. Shonk,et al.  Role of Increased Cerebral myo‐Inositol in the Dementia of Down Syndrome , 1995, Magnetic resonance in medicine.

[20]  W. Chen,et al.  Dynamics of brain structure and cognitive function in the Alzheimer's disease neuroimaging initiative , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[21]  H. Braak,et al.  [Morphological changes in the human cerebral cortex in dementia]. , 1991, Journal fur Hirnforschung.

[22]  O. Okonkwo,et al.  Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia , 2008, Alzheimer's & Dementia.

[23]  M. Castillo,et al.  Clinical applications of proton MR spectroscopy. , 1996, AJNR. American journal of neuroradiology.

[24]  J. Ranjeva,et al.  High cerebral scyllo-inositol: a new marker of brain metabolism disturbances induced by chronic alcoholism , 2004, Magnetic Resonance Materials in Physics, Biology and Medicine.

[25]  Kenneth Rockwood,et al.  Comparison of Machine Learning Techniques with Classical Statistical Models in Predicting Health Outcomes , 2004, MedInfo.

[26]  A. Haley,et al.  Increased glucose concentration in the hippocampus in early Alzheimer's disease following oral glucose ingestion. , 2006, Magnetic resonance imaging.

[27]  E G Tangalos,et al.  Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.

[28]  Zenon Starčuk,et al.  Quantitation of magnetic resonance spectroscopy signals: the jMRUI software package , 2009 .

[29]  Yunting Zhang,et al.  Combining Structural Brain Changes Improves the Prediction of Alzheimer’s Disease and Mild Cognitive Impairment , 2012, Dementia and Geriatric Cognitive Disorders.

[30]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[31]  U. Klose Measurement sequences for single voxel proton MR spectroscopy. , 2008, European journal of radiology.

[32]  Clinical MR Neuroimaging: Diffusion, Perfusion and Spectroscopy , 2006 .

[33]  D L Hardy,et al.  Spectral editing technique for the in vitro and in vivo detection of taurine. , 1998, Journal of magnetic resonance.

[34]  Manjari Tripathi,et al.  Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. , 2012, Biochemical and biophysical research communications.

[35]  P Sachdev,et al.  Magnetic resonance spectroscopy in AD , 2001, Neurology.

[36]  K. Abe,et al.  Magnetic resonance spectroscopic study of Alzheimer's disease and frontotemporal dementia/Pick complex , 2006, Neuroreport.

[37]  F Träber,et al.  A multicenter 1H-MRS study of the medial temporal lobe in AD and MCI , 2009, Neurology.

[38]  S. Borson,et al.  Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. , 2013, JAMA neurology.

[39]  Jennifer L. Whitwell,et al.  Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes. , 2008, Archives of neurology.

[40]  Kevin M Bradley,et al.  Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. , 2002, Brain : a journal of neurology.

[41]  Heinrich Lanfermann,et al.  Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy , 2009, Psychiatry Research: Neuroimaging.

[42]  E. Zamrini,et al.  Elevated brain scyllo‐inositol concentrations in patients with Alzheimer's disease , 2007, NMR in biomedicine.

[43]  Kevin Murphy,et al.  Temporal dynamics of lactate concentration in the human brain during acute inspiratory hypoxia , 2013, Journal of magnetic resonance imaging : JMRI.

[44]  Claudius Mueller,et al.  Longitudinal Metabolic and Cognitive Changes in Mild Cognitive Impairment Patients , 2008, Alzheimer disease and associated disorders.

[45]  L DelaBarre,et al.  The return of the frequency sweep: designing adiabatic pulses for contemporary NMR. , 2001, Journal of magnetic resonance.

[46]  Dennis W J Klomp,et al.  Short echo time 1H‐MRSI of the human brain at 3T with minimal chemical shift displacement errors using adiabatic refocusing pulses , 2008, Magnetic resonance in medicine.

[47]  J. Yesavage,et al.  MR spectroscopy for assessment of memantine treatment in mild to moderate Alzheimer dementia. , 2011, Journal of Alzheimer's disease : JAD.

[48]  Douglas L Rothman,et al.  Magnetic resonance spectroscopy of neurotransmitters in human brain , 2003, Annals of neurology.

[49]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[50]  J. Frahm,et al.  On the identification of cerebral metabolites in localized 1H NMR spectra of human brain In vivo , 1991, NMR in biomedicine.

[51]  Wen-Jang Chu,et al.  Robust fully automated shimming of the human brain for high‐field 1H spectroscopic imaging , 2006, Magnetic resonance in medicine.

[52]  P. V. van Zijl,et al.  Comparison of single‐shot localization methods (steam and press) for In vivo proton NMR spectroscopy , 1989, NMR in biomedicine.

[53]  Andrew Simmons,et al.  Combining MRI and MRS to distinguish between Alzheimer's disease and healthy controls. , 2010, Journal of Alzheimer's disease : JAD.

[54]  Jong Hun Kim,et al.  Neurochemical alterations of the entorhinal cortex in amnestic mild cognitive impairment (aMCI): a three-year follow-up study. , 2012, Archives of gerontology and geriatrics.

[55]  J. Morris,et al.  Clinical core of the Alzheimer's disease neuroimaging initiative: Progress and plans , 2010, Alzheimer's & Dementia.

[56]  S. Byrd,et al.  Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, Part I: Introduction to MRS. , 1996, Journal of the National Medical Association.

[57]  J. Duyn,et al.  Quantitative proton MR spectroscopic imaging of the human brain , 1996, Magnetic resonance in medicine.

[58]  S. Santi,et al.  Memantine decreases hippocampal glutamate levels: A magnetic resonance spectroscopy study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[59]  I. Akiguchi,et al.  Hippocampal metabolites and memory performances in patients with amnestic mild cognitive impairment and Alzheimer’s disease , 2012, Neurobiology of Learning and Memory.

[60]  R. Menon,et al.  Comparison of the quantification precision of human short echo time 1H spectroscopy at 1.5 and 4.0 Tesla , 2000, Magnetic resonance in medicine.

[61]  P. Barker,et al.  Single‐voxel proton MRS of the human brain at 1.5T and 3.0T , 2001, Magnetic resonance in medicine.

[62]  C. Jack,et al.  Risk of dementia in MCI , 2009, Neurology.

[63]  D. Westaway,et al.  Focally Elevated Creatine Detected in Amyloid Precursor Protein (APP) Transgenic Mice and Alzheimer Disease Brain Tissue* , 2006, Journal of Biological Chemistry.

[64]  J. S. Cheung,et al.  Magnetic Resonance Characterization of Ischemic Tissue Metabolism , 2011, The open neuroimaging journal.

[65]  Oded Gonen,et al.  Metabolite ratios to assumed stable creatine level may confound the quantification of proton brain MR spectroscopy. , 2003, Magnetic resonance imaging.

[66]  H. R. Griffith,et al.  Proton magnetic resonance spectroscopy in dementias and mild cognitive impairment. , 2009, International review of neurobiology.

[67]  Hyun Young Lee,et al.  Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimer’s Disease Spectrum Using 3-Tesla MR Spectroscopy , 2012, Dementia and Geriatric Cognitive Disorders.

[68]  K. Abe,et al.  Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease , 2002, Neuroreport.

[69]  D. G. Clark,et al.  Brain Metabolic Correlates of Decision Making in Amnestic Mild Cognitive Impairment , 2010, Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.

[70]  N. Fayed,et al.  Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. , 2008, Academic radiology.

[71]  E. Sullivan,et al.  Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease , 2000, The Lancet.

[72]  C. Jack,et al.  Alzheimer disease: postmortem neuropathologic correlates of antemortem 1H MR spectroscopy metabolite measurements. , 2008, Radiology.

[73]  N. Schuff,et al.  Effects of Alzheimer Disease on Fronto-parietal Brain N-acetyl Aspartate and Myo-Inositol Using Magnetic Resonance Spectroscopic Imaging , 2006, Alzheimer disease and associated disorders.

[74]  K. Kantarci Magnetic resonance spectroscopy in common dementias. , 2013, Neuroimaging clinics of North America.

[75]  N. Fayed,et al.  Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy , 2010, European journal of neurology.

[76]  Chris Frost,et al.  Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. , 2010, Brain : a journal of neurology.

[77]  J. Molinuevo,et al.  Longitudinal Study of Amnesic Patients at High Risk for Alzheimer’s Disease: Clinical, Neuropsychological and Magnetic Resonance Spectroscopy Features , 2007, Dementia and Geriatric Cognitive Disorders.

[78]  S. Moon,et al.  Functional Investigation of Bilateral Posterior Cingulate Gyri Using Multivoxel MR Spectroscopy , 2012, European Neurology.

[79]  Neil L. Harrison,et al.  Taurine Is a Potent Activator of Extrasynaptic GABAA Receptors in the Thalamus , 2008, The Journal of Neuroscience.

[80]  N. Agarwal,et al.  Proton MR Spectroscopy–Detectable Major Neurotransmitters of the Brain: Biology and Possible Clinical Applications , 2012, American Journal of Neuroradiology.

[81]  N. Fayed,et al.  Longitudinal Magnetic Resonance Spectroscopy as Marker of Cognitive Deterioration in Mild Cognitive Impairment , 2011, American journal of Alzheimer's disease and other dementias.

[82]  Jonathan Graff-Radford,et al.  Magnetic resonance spectroscopy in Alzheimer’s disease , 2013, Neuropsychiatric disease and treatment.

[83]  Ewald Moser,et al.  7‐T MR—from research to clinical applications? , 2012, NMR in biomedicine.

[84]  C. Rowe,et al.  Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.

[85]  K Uğurbil,et al.  Observation of resolved glucose signals in 1H NMR spectra of the human brain at 4 Tesla , 1996, Magnetic resonance in medicine.

[86]  Kiyohiro Houkin,et al.  In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. , 2004, Magnetic resonance imaging.

[87]  N. Henigsberg,et al.  1-H MRS changes in dorsolateral prefrontal cortex after donepezil treatment in patients with mild to moderate Alzheimer's disease. , 2011, Collegium antropologicum.

[88]  P. Renshaw,et al.  Biexponential transverse relaxation (T2) of the proton MRS creatine resonance in human brain , 2002, Magnetic resonance in medicine.

[89]  N. Raz,et al.  Differential Aging of the Brain: Patterns, Cognitive Correlates and Modifiers , 2022 .

[90]  Kuncheng Li,et al.  Regional metabolic changes in the hippocampus and posterior cingulate area detected with 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive impairment and alzheimer disease , 2009, Acta radiologica.

[91]  K. Forbes,et al.  Clinical MR neuroimaging: diffusion, perfusion and spectroscopy , 2006, Acta Neurochirurgica.

[92]  A. Spotti,et al.  Proton magnetic resonance spectroscopy: clinical applications in patients with brain lesions. , 2003, Sao Paulo medical journal = Revista paulista de medicina.

[93]  K. Kantarci 1H magnetic resonance spectroscopy in dementia. , 2007, The British journal of radiology.

[94]  H. Heinze,et al.  Association of 1H-MR spectroscopy and cerebrospinal fluid biomarkers in Alzheimer's disease: Diverging behavior at three different brain regions , 2012, Alzheimer's & Dementia.

[95]  Melissa Terpstra,et al.  Noninvasive quantification of ascorbate and glutathione concentration in the elderly human brain , 2011, NMR in biomedicine.

[96]  F A Howe,et al.  The clinical value of proton magnetic resonance spectroscopy in adult brain tumours. , 2007, Clinical radiology.

[97]  Single voxel magnetic resonance spectroscopy at 3 Tesla in a memory disorders clinic: Early right hippocampal NAA/Cr loss in mildly impaired subjects , 2008, Psychiatry Research: Neuroimaging.

[98]  Patrizia Mecocci,et al.  Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.

[99]  Anders M. Fjell,et al.  Neuroimaging Results Impose New Views on Alzheimer’s Disease—the Role of Amyloid Revised , 2011, Molecular Neurobiology.

[100]  Rolf Gruetter,et al.  Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: Detection of high GABA concentrations , 2006, Magnetic resonance in medicine.

[101]  Tao Wang,et al.  Using proton magnetic resonance spectroscopy to identify mild cognitive impairment , 2011, International Psychogeriatrics.

[102]  Z H Cho,et al.  Measurement of the magnetic susceptibility effect in high-field NMR imaging. , 1988, Physics in medicine and biology.

[103]  N. Fayed,et al.  Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. , 2005, The American journal of psychiatry.

[104]  A. Schousboe,et al.  Utilization of glutamine and of TCA cycle constituents as precursors for transmitter glutamate and GABA. , 1993, Developmental neuroscience.

[105]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Superior to Relative Ratio to Discriminate Alzheimer’s Disease from Binswanger’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.

[106]  C. Jack,et al.  Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T. , 2003, AJNR. American journal of neuroradiology.

[107]  C. Bottino,et al.  Proton Spectroscopy in Alzheimer’s Disease and Cognitive Impairment No Dementia: A Community-Based Study , 2008, Dementia and Geriatric Cognitive Disorders.

[108]  H. Lei,et al.  A localized double‐quantum filter for in vivo detection of taurine , 1999, Magnetic resonance in medicine.

[109]  G Tedeschi,et al.  High-field proton MRS of human brain. , 2003, European journal of radiology.

[110]  R. Bartha,et al.  Reduced hippocampal glutamate in Alzheimer disease , 2011, Neurobiology of Aging.

[111]  Norbert Schuff,et al.  Scyllo‐inositol in normal aging human brain: 1H magnetic resonance spectroscopy study at 4 Tesla , 2005, NMR in biomedicine.

[112]  J. Frahm,et al.  Identification of scyllo‐inositol in proton NMR spectra of human brain in vivo , 1993, NMR in biomedicine.

[113]  O. Okonkwo,et al.  Executive function is associated with brain proton magnetic resonance spectroscopy in amnestic mild cognitive impairment , 2007, Journal of clinical and experimental neuropsychology.

[114]  T. Goldberg,et al.  An Open-Label Exploratory Study with Memantine: Correlation between Proton Magnetic Resonance Spectroscopy and Cognition in Patients with Mild to Moderate Alzheimer's Disease , 2012, Dementia and Geriatric Cognitive Disorders Extra.

[115]  S. Chantal,et al.  Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease , 2004, Brain Research.

[116]  Suzanne Craft,et al.  Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. , 2007, Current Alzheimer research.

[117]  E G Tangalos,et al.  The incidence of MCI differs by subtype and is higher in men , 2012, Neurology.

[118]  A. Stoll,et al.  Choline ingestion increases the resonance of choline-containing compounds in human brain: An in vivo proton magnetic resonance study , 1995, Biological Psychiatry.

[119]  Chenguang Zhao,et al.  In vivo detection of serine in the human brain by proton magnetic resonance spectroscopy (1H‐MRS) at 7 Tesla , 2009, Magnetic resonance in medicine.

[120]  J. Fisk,et al.  An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study. , 2011, Journal of Alzheimer's disease : JAD.

[121]  D Matthaei,et al.  1H NMR chemical shift selective (CHESS) imaging. , 1985, Physics in medicine and biology.

[122]  Napapon Sailasuta,et al.  A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain. , 2004, Magnetic resonance imaging.

[123]  William H. Oldendorf,et al.  N-Acetyl-L-Aspartic acid: A literature review of a compound prominent in 1H-NMR spectroscopic studies of brain , 1989, Neuroscience & Biobehavioral Reviews.

[124]  I. Akiguchi,et al.  Absolute Quantification in Proton Magnetic Resonance Spectroscopy Is Useful to Differentiate Amnesic Mild Cognitive Impairment from Alzheimer’s Disease and Healthy Aging , 2010, Dementia and Geriatric Cognitive Disorders.

[125]  P. Bottomley Spatial Localization in NMR Spectroscopy in Vivo , 1987, Annals of the New York Academy of Sciences.

[126]  K. Rockwood,et al.  Evaluation of Common Structural Brain Changes in Aging and Alzheimer Disease with the Use of an MRI-Based Brain Atrophy and Lesion Index: A Comparison Between T1WI and T2WI at 1.5T and 3T , 2014, American Journal of Neuroradiology.

[127]  Randall S. Jones,et al.  1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia , 2004, Neurological research.

[128]  M. Reger,et al.  Statin users without an APOE-epsilon4 allele have increased insulin resistance. , 2010, Journal of Alzheimer's disease : JAD.

[129]  N. Fayed,et al.  Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study , 2011, BMJ Open.

[130]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[131]  K. Uğurbil,et al.  Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia , 2005, Magnetic Resonance Materials in Physics, Biology and Medicine.

[132]  Dae-Shik Kim,et al.  High-field magnetic resonance techniques for brain research , 2003, Current Opinion in Neurobiology.

[133]  Aki Vehtari,et al.  A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. , 2008, Biochemical and biophysical research communications.

[134]  Gülin Öz,et al.  Regional neurochemical profiles in the human brain measured by 1H MRS at 7 T using local B1 shimming , 2012, NMR in biomedicine.

[135]  E. Barbeau,et al.  Impaired visual recognition memory in amnestic mild cognitive impairment is associated with mesiotemporal metabolic changes on magnetic resonance spectroscopic imaging. , 2011, Journal of Alzheimer's disease : JAD.

[136]  R. Bartha,et al.  Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[137]  Peter Andersen,et al.  In vivo 1H NMR spectroscopy of the human brain at 9.4 T: initial results. , 2010, Journal of magnetic resonance.

[138]  K O Lim,et al.  In vivo spectroscopic quantification of the N‐acetyl moiety, creatine, and choline from large volumes of brain gray and white matter: Effects of normal aging , 1999, Magnetic resonance in medicine.

[139]  D J Drost,et al.  Factors affecting the quantification of short echo in‐vivo 1H MR spectra: prior knowledge, peak elimination, and filtering , 1999, NMR in biomedicine.

[140]  Brian J Soher,et al.  A review of 1H MR spectroscopy findings in Alzheimer's disease. , 2005, Neuroimaging clinics of North America.

[141]  J. Frahm,et al.  Differential distribution of NAA and NAAG in human brain as determined by quantitative localized proton MRS , 1997, NMR in biomedicine.

[142]  B. Miller A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.